Skip to main content

Table 3 Identity and amounts of related substances and impurities in seven generic products compared to Madopar®/Prolopa® specifications

From: Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®

Degradation product

Ro 04-1419

Ro 08-1580

Ro 04-1419 + Ro 08-1580

Others each

Others total

Tablets Upper limits (%)

1.54

2.49

3.49

0.54

1.04

Levodopa/ Benserazid beta

0.35

0.47

0.83

0.19, 0.09

0.28

Levodopa/ Benserazid-CT

0.28

0.48

0.75

0.09, 0.08

0.17

Levodopa/ Benserazide ratiopharm

0.25

0.37

0.62

0.16, 0.05

0.21

dopadura B

0.26

0.34

0.60

0.12

0.12

Capsules Upper limits (%)

0.54

0.54

0.49

0.24

0.54

Levopar

0.12

0.34

0.46

0.10

0.10

Levodopa comp. B STADA

0.16

0.32

0.49

0.11, 0.11

0.11

Levobens-Teva

0.36

0.25

0.62*

0.10, 0.12, 0.10

0.33

  1. *Values marked with an asterisk indicate deviations from Roche specifications.